Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how leukemia drug works outside the lab

NCT ID NCT06092879

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather practical information that goes beyond clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
asciminib (Scemblix)
What this could lead to
If successful, this study could provide real-world evidence on how well asciminib works and is tolerated in everyday practice for patients with chronic myeloid leukemia who have tried other treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and real-world variability. It does not test a new treatment but gathers data on existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

201 people

The number who actually took part.

Started

Mar 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient aged ≥ 18 years at inclusion, 2. Patient with Ph+ CML-CP previously treated with two or more TKIs, 3. Patient for whom a decision has been taken by the treating physician (investigator) to initiate treatment with asciminib according to his own practice, the drug label / Summary of Product Characteristics (SmPC), and regardless of study participation, 4. Patient having given their non objection to participate to the study Exclusion Criteria: 1. Patient with CML in accelerated phase (AP) or blastic phase (BP) at enrolment, 2. Patient with known history of T315I mutation, 3. Patient who previously received asciminib treatment, 4. Patient currently participating to an interventional clinical trial, 5. Patient with known contra-indication to asciminib according to the SmPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic myeloid leukemia

Contacts and locations

Locations

  • Novartis Investigative Site

    Angers, France, 49933, France

  • Novartis Investigative Site

    Limoges, Haute Vienne, 87000, France

  • Novartis Investigative Site

    Saint Priest Jarez, Pays de la Loire Region, 42270, France

  • Novartis Investigative Site

    Aix-en-Provence, 13616, France

  • Novartis Investigative Site

    Amiens, 80054, France

  • Novartis Investigative Site

    Antibes, 06600, France

  • Novartis Investigative Site

    Avignon, 84000, France

  • Novartis Investigative Site

    Besançon, 25030, France

  • Novartis Investigative Site

    Bobigny, 93009, France

  • Novartis Investigative Site

    Bordeaux, 33000, France

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Brest, 29609, France

  • Novartis Investigative Site

    Brive-la-Gaillarde, 19100, France

  • Novartis Investigative Site

    Caen, 14033, France

  • Novartis Investigative Site

    Cagnes-sur-Mer, 06800, France

  • Novartis Investigative Site

    Cannes, 06414, France

  • Novartis Investigative Site

    Castelnau-le-Lez, 34170, France

  • Novartis Investigative Site

    Cesson-Sévigné, 35576, France

  • Novartis Investigative Site

    Chambéry, 73000, France

  • Novartis Investigative Site

    Clermont-Ferrand, 63003, France

  • Novartis Investigative Site

    Corbeil-Essonnes, 91100, France

  • Novartis Investigative Site

    Dunkirk, 59240, France

  • Novartis Investigative Site

    Essey-lès-Nancy, 54270, France

  • Novartis Investigative Site

    Grenoble, 38043, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, 94275, France

  • Novartis Investigative Site

    Le Mans, 72000, France

  • Novartis Investigative Site

    Lens, 62307, France

  • Novartis Investigative Site

    Libourne, 33505, France

  • Novartis Investigative Site

    Lorient, 56100, France

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Montpellier, 34070, France

  • Novartis Investigative Site

    Montpellier, 34295, France

  • Novartis Investigative Site

    Mulhouse, 68070, France

  • Novartis Investigative Site

    Nantes, 44277, France

  • Novartis Investigative Site

    Nevers, 58000, France

  • Novartis Investigative Site

    Nîmes, 30029, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Paris, 75015, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Perpignan, 66046, France

  • Novartis Investigative Site

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Quimper, 29000, France

  • Novartis Investigative Site

    Rennes, 35033, France

  • Novartis Investigative Site

    Roubaix, 59100, France

  • Novartis Investigative Site

    Strasbourg, 67085, France

  • Novartis Investigative Site

    Tarbes, 65100, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Tours, 37044, France

  • Novartis Investigative Site

    Valence, 26953, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, 54511, France

  • Novartis Investigative Site

    Vesoul, 70014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.